Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of vonoprazan 20 mg vs VOCINTI 20 mg in healthy Thai participants under fasting conditions
TCTR20260320006Phase 1Not yet recruiting
- Sponsor
- Bio-innova
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vonoprazan (2 arms), sponsored by Bio-innova. Primary endpoint: Primary pharmacokinetic bioequivalence endpoints. Planned start May 2026; status: not yet recruiting.
02
Drugs
vonoprazan
Beyond the preview
Go deeper on TCTR20260320006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260320006.